Fábio Oliveira

Dr. Fábio Oliveira


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Toxicon
Verified
Journal Article
Closed access
MQMayara Ribeiro de Queiroz
Mayara Ribeiro de Queiroz
BSBruna Barbosa de Sousa
Bruna Barbosa de Sousa
DPDéborah Fernanda da Cunha Pereira
Déborah Fernanda da Cunha Pereira
CMCarla Cristine Neves Mamede
Carla Cristine Neves Mamede
MMMariana Santos Matias
Mariana Santos Matias
FOFábio Oliveira
Fábio Oliveira

1 July 2016 in Toxicon
Verified
Journal Article
Closed access
CMCarla Cristine Neves Mamede
Carla Cristine Neves Mamede
BSBruna Barbosa de Sousa
Bruna Barbosa de Sousa
DPDéborah Fernanda da Cunha Pereira
Déborah Fernanda da Cunha Pereira
MMMariana Santos Matias
Mariana Santos Matias
MQMayara Ribeiro de Queiroz
Mayara Ribeiro de Queiroz
FOFábio de Oliveira
Fábio de Oliveira

30 November 2015 in Toxins
Verified
Journal Article
Open access
PDF file
MSMariana Silva
Mariana Silva
CMCaroline Martins Mota
Caroline Martins Mota
VMVanessa Dos Santos Miranda
Vanessa Dos Santos Miranda
ACAmanda De Oliveira Cunha
Amanda De Oliveira Cunha
MSMaraisa Silva
Maraisa Silva
FSFernanda Santiago
Fernanda Santiago
Hymenoptera venoms constitute an interesting source of natural toxins that may lead to the development of novel therapeutic agents. The present study investigated the enzymatic and biological characteristics of the crude venom of the ant Odontomachus bauri. Its crude venom presents several protein bands, with higher staining for six proteins with gelatinolytic activity (17, 20, 26, 29, 43 and 48 kDa). The crude venom showed high proteolytic activity on azocasein at optimal pH 8.0 and 37 °C. In the presence of protease inhibitors as aprotinin, leupeptin and EDTA, the azocaseinolytic activity was reduced by 45%, 29% and 9%, respectively, suggesting that the enzymes present in the crude venom belong to the three classes of proteases, with the serine proteases in greater intensity. The crude venom degraded the fibrinogen α-chain faster than the β-chain, while the fibrinogen γ-chain remained unchanged. In biological assays, O. bauri venom showed hemolytic and coagulant activity in vitro, and defibrinating activity in vivo. In addition, the venom showed antimicrobial activity against Staphylococcus aureus and Escherichia coli as well as antiparasitic activity on Toxoplasma gondii infection in vitro. In that sense, this study sheds perspectives for pharmacological applications of O. bauri venom enzymes.

1 March 2016 in Toxicon
Verified
Journal Article
Closed access
FOFábio de Oliveira
Fábio de Oliveira
BSBruna Barbosa de Sousa
Bruna Barbosa de Sousa
CMCarla Cristine Neves Mamede
Carla Cristine Neves Mamede
NMNadia Cristina Gomes de Morais
Nadia Cristina Gomes de Morais
MQMayara Ribeiro de Queiroz
Mayara Ribeiro de Queiroz
MBMaria Inês Homi Brandeburgo
Maria Inês Homi Brandeburgo

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MQMayara R. de Queiroz
Mayara R. de Queiroz
CMCarla C. Neves Mamede
Carla C. Neves Mamede
KFKelly C. Fonseca
Kelly C. Fonseca
NMNadia C. G. de Morais
Nadia C. G. de Morais
BSBruna B. de Sousa
Bruna B. de Sousa
FOFábio Oliveira
Fábio Oliveira
The present study aimed to evaluate the proteolytic and biological activities of a new metalloproteinase fromB. moojenivenom. The purification of BmooMPα-II was carried out through two chromatographic steps (ion-exchange and affinity). BmooMPα-II is a monomeric protein with an apparent molecular mass of 22.5 kDa on SDS-PAGE 14% under nonreducing conditions. The N-terminal sequence (FSPRYIELVVVADHGMFTKYKSNLN) revealed homology with other snake venom metalloproteinases, mainly among P-I class. BmooMPα-II cleaves Aα-chain of fibrinogen followed by Bβ-chain, and does not show any effect on theγ-chain. Its optimum temperature and pH for the fibrinogenolytic activity were 30–50°C and pH 8, respectively. The inhibitory effects of EDTA and 1,10-phenantroline on the fibrinogenolytic activity suggest that BmooMPα-II is a metalloproteinase. This proteinase was devoid of haemorrhagic, coagulant, or anticoagulant activities. BmooMPα-II caused morphological alterations in liver, lung, kidney, and muscle of Swiss mice. The enzymatically active protein yet inhibited collagen, ADP, and ristocetin-induced platelet aggregation in a concentration-dependent manner. Our results suggest that BmooMPα-II contributes to the toxic effect of the envenomation and that more investigations to elucidate the mechanisms of inhibition of platelet aggregation may contribute to the studies of snake venom on thrombotic disorders.

20 July 2016 in Toxins
Verified
Journal Article
Open access
PDF file
MSMaraisa Cristina Silva
Maraisa Cristina Silva
TSTamires Lopes Silva
Tamires Lopes Silva
MSMurilo Vieira Silva
Murilo Vieira Silva
CMCaroline Martins Mota
Caroline Martins Mota
FSFernanda Santiago
Fernanda Santiago
JMJose Roberto Mineo
Jose Roberto Mineo
Tumor necrosis factor (TNF) is a major cytokine in inflammatory processes and its deregulation plays a pivotal role in several diseases. Here, we report that a zinc metalloprotease extracted from Bothrops moojeni venom (BmooMP-alpha-I) inhibits TNF directly by promoting its degradation. This inhibition was demonstrated by both in vitro and in vivo assays, using known TLR ligands. These findings are supported by molecular docking results, which reveal interaction between BmooMP-alpha-I and TNF. The major cluster of interaction between BmooMP-alpha-I and TNF was confirmed by the structural alignment presenting Ligand Root Mean Square Deviation LRMS = 1.05 Å and Interactive Root Mean Square Deviation IRMS = 1.01 Å, this result being compatible with an accurate complex. Additionally, we demonstrated that the effect of this metalloprotease on TNF is independent of cell cytotoxicity and it does not affect other TLR-triggered cytokines, such as IL-12. Together, these results indicate that this zinc metalloprotease is a potential tool to be further investigated for the treatment of inflammatory disorders involving TNF deregulation.